Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

New U.S. Patent Allowance Granted to Mastix LLC for a New Chewing Gum Manufacturing Method Incorporating Cannabinoids

Mastix
Posted on: 25 Jul 17

HUNT VALLEY, Md., July 25, 2017 /PRNewswire/ -- Mastix LLC, a leading manufacturer of innovative functional supplement products, today announces that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application 14/732,072, a utility patent that claims a new manufacturing method for functional chewing gum that covers powder and oil-based active ingredients, including cannabidiol (CBD) and tetrahydrocannabinol (THC). This platform patent technology covers the inclusion of a wide range of active ingredients, including cannabinoids (both naturally extracted and synthetically derived), which is a market experiencing explosive growth.

"The granting of this notice of allowance for our novel chewing gum dosage form validates the innovative nature of our platform technology and positions us well to offer our customers and consumers an alternative delivery system to pills, capsules and beverages that is widely acceptable and very familiar," said Bob Estey, CEO of Mastix. "We have the unique ability to incorporate either a single active ingredient, or multiple active ingredients, into the gum tablets we make to provide our customers with truly custom chewing gum products that will now be patent protected. Consumers are actively seeking alternative delivery vehicles for the many pharmaceutical and supplement products they currently take as pills or capsules. Chewing gum is a convenient and discrete way for consumers to quickly and efficiently deliver the benefits they expect from the products they use to improve their health and wellness. The extensive clinical studies the US Military performed on our caffeine gum proved that gum delivered through the oral mucosa is up to five times faster than swallowing pills or capsules while also maintaining high bioavailability of the active."

In addition to its proprietary CBD gum (www.medcbdx.com), Mastix offers custom development, contract manufacturing and private label for its chewing gum, lozenge and chewable tablet products. Mastix has developed tableted products in a wide range of active ingredients including dietary supplements, herbal extracts, probiotics and cannabinoids, and is best known as the supplier of caffeine chewing gum for the US Military ration kits.

About Mastix LLC
Mastix LLC develops, manufactures and markets niche functional food and dietary supplement products in chewing gum, chewable tablet and lozenge dosage formats. Mastix manufactures its products in full compliance with FDA GMP regulations.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE: The statements presented in this press release have not been evaluated by the FDA and are not intended to diagnose, treat, cure or prevent any disease.

LEGAL DISCLOSURE
Mastix LLC does not develop, manufacture, sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 25/07/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.